These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
536 related articles for article (PubMed ID: 33119877)
21. Genetically Induced Tumors in the Oncopig Model Invoke an Antitumor Immune Response Dominated by Cytotoxic CD8β Overgaard NH; Principe DR; Schachtschneider KM; Jakobsen JT; Rund LA; Grippo PJ; Schook LB; Jungersen G Front Immunol; 2018; 9():1301. PubMed ID: 29930558 [TBL] [Abstract][Full Text] [Related]
22. Characterization of tumor reactivity of human V gamma 9V delta 2 gamma delta T cells in vitro and in SCID mice in vivo. Kabelitz D; Wesch D; Pitters E; Zöller M J Immunol; 2004 Dec; 173(11):6767-76. PubMed ID: 15557170 [TBL] [Abstract][Full Text] [Related]
23. Gamma Delta T-Cell Based Cancer Immunotherapy: Past-Present-Future. Saura-Esteller J; de Jong M; King LA; Ensing E; Winograd B; de Gruijl TD; Parren PWHI; van der Vliet HJ Front Immunol; 2022; 13():915837. PubMed ID: 35784326 [TBL] [Abstract][Full Text] [Related]
24. Phosphoantigens and butyrophilin 3A1 induce similar intracellular activation signaling in human TCRVγ9+ γδ T lymphocytes. Decaup E; Duault C; Bezombes C; Poupot M; Savina A; Olive D; Fournié JJ Immunol Lett; 2014 Sep; 161(1):133-7. PubMed ID: 24925024 [TBL] [Abstract][Full Text] [Related]
26. Improving the Efficiency of Vγ9Vδ2 T-Cell Immunotherapy in Cancer. Hoeres T; Smetak M; Pretscher D; Wilhelm M Front Immunol; 2018; 9():800. PubMed ID: 29725332 [TBL] [Abstract][Full Text] [Related]
27. Protective role of the inflammatory CCR2/CCL2 chemokine pathway through recruitment of type 1 cytotoxic γδ T lymphocytes to tumor beds. Lança T; Costa MF; Gonçalves-Sousa N; Rei M; Grosso AR; Penido C; Silva-Santos B J Immunol; 2013 Jun; 190(12):6673-80. PubMed ID: 23686489 [TBL] [Abstract][Full Text] [Related]
28. Regulatory and effector functions of gamma-delta (γδ) T cells and their therapeutic potential in adoptive cellular therapy for cancer. Paul S; Lal G Int J Cancer; 2016 Sep; 139(5):976-85. PubMed ID: 27012367 [TBL] [Abstract][Full Text] [Related]
29. Butyrophilin3A proteins and Vγ9Vδ2 T cell activation. Gu S; Borowska MT; Boughter CT; Adams EJ Semin Cell Dev Biol; 2018 Dec; 84():65-74. PubMed ID: 29471037 [TBL] [Abstract][Full Text] [Related]
30. Function of γδ T cells in tumor immunology and their application to cancer therapy. Park JH; Lee HK Exp Mol Med; 2021 Mar; 53(3):318-327. PubMed ID: 33707742 [TBL] [Abstract][Full Text] [Related]
31. Preferential Infiltration of Unique Vγ9Jγ2-Vδ2 T Cells Into Glioblastoma Multiforme. Lee M; Park C; Woo J; Kim J; Kho I; Nam DH; Park WY; Kim YS; Kong DS; Lee HW; Kim TJ Front Immunol; 2019; 10():555. PubMed ID: 30967876 [TBL] [Abstract][Full Text] [Related]
32. Deciphering human γδ T cell response in cancer: Lessons from tumor-infiltrating γδ T cells. Lo Presti E; Dieli F; Fourniè JJ; Meraviglia S Immunol Rev; 2020 Nov; 298(1):153-164. PubMed ID: 32691450 [TBL] [Abstract][Full Text] [Related]
33. Repeated systemic administrations of both aminobisphosphonates and human Vγ9Vδ2 T cells efficiently control tumor development in vivo. Santolaria T; Robard M; Léger A; Catros V; Bonneville M; Scotet E J Immunol; 2013 Aug; 191(4):1993-2000. PubMed ID: 23836057 [TBL] [Abstract][Full Text] [Related]
34. gammadelta T cells in cancer immunotherapy: current status and future prospects. Chiplunkar S; Dhar S; Wesch D; Kabelitz D Immunotherapy; 2009 Jul; 1(4):663-78. PubMed ID: 20635991 [TBL] [Abstract][Full Text] [Related]
35. Anti-tumour immunotherapy with Vγ9Vδ2 T lymphocytes: from the bench to the bedside. Braza MS; Klein B Br J Haematol; 2013 Jan; 160(2):123-32. PubMed ID: 23061882 [TBL] [Abstract][Full Text] [Related]